Bútová Romana, Vychytilová-Faltejsková Petra, Gregorová Jana, Radová Lenka, Almáši Martina, Bezděková Renata, Brožová Lucie, Jarkovský Jiří, Knechtová Zdeňka, Štork Martin, Pour Luděk, Ševčíková Sabina
Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Department of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic.
Biomedicines. 2021 Nov 8;9(11):1637. doi: 10.3390/biomedicines9111637.
Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs ( < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
长链非编码RNA（lncRNAs）是长度超过200个核苷酸的功能性RNA。由于现代基因组技术的发展，lncRNAs在肿瘤发生中的作用已被揭示；然而，关于lncRNAs在多发性骨髓瘤（MM）和浆细胞白血病（PCL）中的相互作用的信息实际上并不存在。在此，我们旨在鉴定参与MM向PCL进展的lncRNAs。我们使用下一代测序技术研究了MM和PCL患者的代表性数据集。总共鉴定出13种失调的lncRNAs（<0.00025）；其中4种被选用于通过RT-qPCR在一组独立的MM和PCL患者中进行进一步验证。所得结果证明，与MM相比，PCL中淋巴细胞抗原反义RNA 1（LY86-AS1）和波形蛋白反义RNA 1（VIM-AS1）显著下调。重要的是，这两种lncRNAs可能参与MM向PCL的进展；因此，它们有望成为MM进展的新型生物标志物。
